“Thrilled to see Hanson Wade taking on the emerging science of in vivo cell engineering. I strongly believe that combining genomics with cell biology will unleash a revolution in medicine”
Oscar Segurado, Chief Medical Officer, ASC Therapeutics

“Ex vivo engineering of therapeutic cells, such as CAR T-cells, has shown amazing therapeutic promise. However, the complex logistics and cost have limited patient access. In vivo cell engineering offers the potential to achieve the same therapeutic benefits in more patients at lower cost”
Andy Scharenberg, Chief Executive Officer, Umoja Biopharma

“Reprogramming cells directly inside a patient has the potential to have a dramatic impact on patient outcomes because we have the opportunity to empower patients’ own immune system rather than a single immune cell type”
Nicholas Boyle, Chief Executive Officer, Abintus Bio

“The speed at which in vivo gene delivery to immune cells has matured has been fierce. So glad that HW is organizing the first ever dedicated meeting where we can discuss in depth and meet with colleagues to bring these exciting modalities to patients. Excited to lead workshop on comparing the various in vivo delivery systems”
David Perrit, Founder & Chief Executive Officer, Lupagen